Retention rates of new antiepileptic drugs in localization-related epilepsy: A single-center study

Acta Neurologica Scandinavica

Volumn 119, Issue 1, 2009, Pages 55-60

  Peltola, J ^a   Peltola, M ^a   Auvinen, A ^b   Raitanen, J ^b   Fallah, M ^a,b   Keranen T ^a,b  

^a TAMPERE UNIVERSITY HOSPITAL   (Finland)

^b TAMPERE UNIVERSITY OF TECHNOLOGY   (Finland)

Author keywords

Antiepileptic drugs; Localization related epilepsy; Retention rates

Indexed keywords

ETIRACETAM; GABAPENTIN; LAMOTRIGINE; TIAGABINE; TOPIRAMATE;

ADOLESCENT; ADULT; AGED; ARTICLE; CLINICAL PRACTICE; CONTROLLED STUDY; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; FOCAL EPILEPSY; FRONTAL LOBE EPILEPSY; HUMAN; MAJOR CLINICAL STUDY; MALE; OCCIPITAL LOBE; PARIETAL LOBE; TEMPORAL LOBE EPILEPSY; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; AMINES; ANTICONVULSANTS; CHILD; CYCLOHEXANECARBOXYLIC ACIDS; EPILEPSY; FEMALE; FINLAND; FRUCTOSE; GAMMA-AMINOBUTYRIC ACID; HALF-LIFE; HUMANS; LICENSURE, PHARMACY; MALE; MIDDLE AGED; NIPECOTIC ACIDS; PIRACETAM; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; TRIAZINES; YOUNG ADULT;

EID: 58149085710     PISSN: 00016314     EISSN: 16000404     Source Type: Journal    
DOI: 10.1111/j.1600-0404.2008.01062.x     Document Type: Article

References (26)

1. Hitiris N, Brodie MJ. Modern antiepileptic drugs: guidelines and beyond. Curr Opin Neurol 2006 19 : 175 80.
2. Sander JW. New antiepileptic drugs in practice - how do they perform in the real world? Acta Neurol Scand 2005 181 (Suppl 26 9.
3. Chaisewikul R, Privitera MD, Hutton JL, Marson AG. Levetiracetam add-on for drug-resistant localization related (partial) epilepsy. Coch Database System Rev 2001 CD001901.
4. Jette NJ, Marson AG, Kadir ZA, Hutton JL. Topiramate for drug-resistant partial epilepsy. Coch Database System Rev 2000 CD001417.
5. Pereira J, Marson AG, Hutton JL. Tiagabine add-on for drug-resistant partial epilepsy. Coch Database System Rev 2002 CD001908.
6. Marson AG, Kadir ZA, Hutton JL, Chadwick DW. The new antiepileptic drugs: a systematic review of their efficacy and tolerability. Epilepsia 1997 38 : 859 80.
7. Lhatoo SD, Wong IC, Polizzi G, Sander JW. Long-term retention rates of lamotrigine, gabapentin, and topiramate in chronic epilepsy. Epilepsia 2000 41 : 1592 6.
8. Rainesalo S, Peltola J, Auvinen A, Keranen T. Retention rate of oxcarbazepine monotherapy in an unselected population of adult epileptics. Seizure 2005 14 : 72 4.
9. Peltola J, Peltola M, Raitanen J, Keranen T, Kharazmi E, Auvinen A. Seizure-freedom with combination therapy in localization-related epilepsy. Seizure 2008 17 : 276 80.
10. Proposal for revised classification of epilepsies, epileptic syndromes. Commission on Classification and Terminology of the International League against Epilepsy. Epilepsia 1989 30 : 389 99.
11. Kaplan EL, Meier P. Nonparametric estimation from incomplete data. J Am Statist Assoc 1958 53 : 457 81.
12. Wong IC, Chadwick DW, Fenwick PB, Mawer GE, Sander JW. The long-term use of gabapentin, lamotrigine, and vigabatrin in patients with chronic epilepsy. Epilepsia 1999 40 : 1439 45.
13. Collins TL, Petroff OA, Mattson RH. A comparison of four new antiepileptic medications. Seizure 2000 9 : 291 3.
14. Schapel G, Chadwick D. A survey comparing lamotrigine and vigabatrin in everyday clinical practice. Seizure 1996 5 : 267 70.
15. Wong IC, Mawer GE, Sander JW, Lhatoo SD. A pharmacoepidemiologic study of factors influencing the outcome of treatment with lamotrigine in chronic epilepsy. Epilepsia 2001 42 : 1354 8.
16. Simister RJ, Sander JW, Koepp MJ. Long-term retention rates of new antiepileptic drugs in adults with chronic epilepsy and learning disability. Epilepsy Behav 2007 10 : 336 9.
17. Chung S, Wang N, Hank N. Comparative retention rates and long-term tolerability of new antiepileptic drugs. Seizure 2007 16 : 296 304.
18. Ben Menachem E, Gilland E. Efficacy and tolerability of levetiracetam during 1-year follow-up in patients with refractory epilepsy. Seizure 2003 12 : 131 5.
19. Depondt C, Yuen AW, Bell GS et al. The long term retention of levetiracetam in a large cohort of patients with epilepsy. J Neurol Neurosurg Psychiatry 2006 77 : 101 3.
20. Nicolson A, Lewis SA, Smith DF. A prospective analysis of the outcome of levetiracetam in clinical practice. Neurology 2004 63 : 568 70.
21. Bootsma HP, Coolen F, Aldenkamp AP et al. Topiramate in clinical practice: long-term experience in patients with refractory epilepsy referred to a tertiary epilepsy center. Epilepsy Behav 2004 5 : 380 7.
22. Lhatoo SD, Wong IC, Sander JW. Prognostic factors affecting long-term retention of topiramate in patients with chronic epilepsy. Epilepsia 2000 41 : 338 41.
23. Aikia M, Jutila L, Salmenpera T, Mervaala E, Kalviainen R. Long-term effects of tiagabine monotherapy on cognition and mood in adult patients with chronic partial epilepsy. Epilepsy Behav 2006 8 : 750 5.
24. Fakhoury T, Uthman B, Abou-Khalil B. Safety of long-term treatment with tiagabine. Seizure 2000 9 : 431 5.
25. Otoul C, Arrigo C, Van Rijckevorsel K, French JA. Meta-analysis and indirect comparisons of levetiracetam with other second-generation antiepileptic drugs in partial epilepsy. Clin Neuropharmacol 2005 28 : 72 8.
26. Deckers CL, Genton P, Sills GJ, Schmidt D. Current limitations of antiepileptic drug therapy: a conference review. Epilepsy Res 2003 53 : 1 17.